期刊
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA
卷 44, 期 2, 页码 99-108出版社
SPRINGER WIEN
DOI: 10.1007/s10353-011-0612-z
关键词
Somatostatin; octreotide; pancreatic surgery; pancreatic fistula; postoperative complications
类别
资金
- Ministry of Health Care, Czech Republic [MZO 00179906]
BACKGROUND: The prophylactic use of somatostatin and its analogs has been suggested to lower the rate of pancreatic fistula. The aim of this review is to discuss the results of published randomized trials and meta-analyses studying the effect of somatostatin and its analogs. METHODS: We performed a Medline search for prospective randomized trials, systematic reviews and meta-analyses with regard to the prophylactic use of somatostatin and its analogs. RESULTS: Eleven randomized trials and six meta-analyses were identified. The randomized trials differ in terms of study designs, diagnosis, operative procedures, drug dosage, time of administration, and the pancreatic fistula definition; therefore, it is advisable to carefully interpret the results of the individual randomized trials. CONCLUSIONS: The routine administration of somatostatin and its analogs in elective pancreatic surgery cannot be recommended. However, selective administration is advisable in cases which carry significantly higher risk of developing pancreatic fistula.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据